<p>Artivion（纽约证券交易所代码：AORT - 获取免费报告）在周五向投资者发布的一份报告中，JMP Securities 的股票研究人员将其目标价格从 33.00 美元上调至 42.00 美元。该券商目前对该股票给予 “市场表现优于大盘” 的评级。JMP Securities 的目标价格暗示该公司股价有 7.93% 的潜在上涨空间。</p>
<p>其他一些股票研究分析师也最近对 AORT 发表了看法。Stifel Nicolaus 在周五的研究报告中将 Artivion 的目标价格从 36.00 美元上调至 40.00 美元，并给予该公司 “买入” 评级。Canaccord Genuity Group 在 6 月 17 日的报告中开始覆盖 Artivion，给予 “买入” 评级和 35.00 美元的目标价格。Citizens Jmp 在 5 月 6 日的报告中将 Artivion 的评级提升至 “强力买入”。最后，Needham &amp; Company LLC 在周五的报告中重申了 “买入” 评级，并将目标价格上调至 45.00 美元（之前为 32.00 美元）。五位分析师对该股票给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，平均目标价格为 38.80 美元。</p>
<p><strong>查看我们对 Artivion 的最新分析</strong></p>
<h2>Artivion 股价上涨 19.0%</h2>
<p>周五，NYSE AORT 的股票在交易中上涨 6.22 美元，达到 38.92 美元。该公司交易了 541,252 股，较其平均交易量 419,484 股有所增加。该公司的 50 日移动平均价格为 30.55 美元，200 日移动平均价格为 27.96 美元。该公司的债务与股本比率为 1.08，速动比率为 3.95，流动比率为 5.53。该公司的市值为 16.6 亿美元，市盈率为-77.80，贝塔值为 1.64。Artivion 的 12 个月低点为 21.97 美元，12 个月高点为 40.56 美元。</p>
<p>Artivion（纽约证券交易所代码：AORT - 获取免费报告）最近于 8 月 7 日发布了其财报。该公司报告本季度每股收益为 0.24 美元，超出市场共识预期的 0.11 美元，超出幅度为 0.13 美元。Artivion 的股本回报率为 3.63%，净利润率为-5.49%。该公司本季度的收入为 1.1297 亿美元，而市场共识预期为 1.0796 亿美元。Artivion 的季度收入同比增长 15.3%。作为一个整体，股票研究分析师预计 Artivion 在当前年度将发布 0.37 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他消息中，董事 Anthony B. Semedo 于 5 月 23 日星期五出售了 2,600 股该股票，交易价格为 28.47 美元，总价值为 74,022.00 美元。出售完成后，该董事在公司持有 33,059 股，价值约为 941,189.73 美元。此交易代表其持股比例减少了 7.29%。该交易已在证券交易委员会的备案中披露，您可以通过此链接访问。此外，SVP Jean F. Holloway 于 5 月 27 日星期二出售了 8,748 股该股票，交易价格为 29.00 美元，总价值为 253,692.00 美元。出售完成后，该高级副总裁持有 178,510 股公司股票，价值约为 5,176,790 美元。此交易代表其持股比例减少了 4.67%。该出售的披露信息可以在这里找到。过去三个月，内部人士共出售了 62,406 股公司股票，价值 1,801,262 美元。内部人士持有该股票的比例为 7.60%。</p>
<h2>机构投资者对 Artivion 的看法</h2>
<p>对该公司的股票，最近对冲基金进行了买入和卖出。Franklin Resources Inc.在第四季度将其在 Artivion 的持股增加了 2.8%。Franklin Resources Inc.目前持有 21,707 股该公司的股票，价值 621,000 美元，此前在上个季度购买了 600 股。伊利诺伊州市政退休基金在第一季度将其在 Artivion 的持股增加了 3.1%。伊利诺伊州市政退休基金目前持有 20,519 股该公司的股票，价值 504,000 美元，此前在上个季度购买了 611 股。MCF Advisors LLC 在第一季度将其在 Artivion 的持股增加了 109.3%。MCF Advisors LLC 目前持有 1,176 股该公司的股票，价值 29,000 美元，此前在上个季度购买了 614 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第四季度将其在 Artivion 的持股增加了 3.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 22,559 股该公司的股票，价值 645,000 美元，此前在上个季度购买了 727 股。最后，巴克莱银行在第四季度将其在 Artivion 的持股增加了 1.2%。巴克莱银行目前持有 71,697 股该公司的股票，价值 2,051,000 美元，此前在上个季度购买了 820 股。机构投资者和对冲基金持有该公司 86.37% 的股票。</p>
<h2>Artivion 公司简介</h2>
<p>（获取免费报告）</p>
<p>Artivion, Inc.在全球范围内制造、加工和分销医疗设备和可植入的人体组织。该公司提供 BioGlue，这是一种由牛血蛋白和交联蛋白的试剂组成的聚合物，适用于心脏、血管、神经和肺部手术；心脏保护服务；PhotoFix，一种牛心包补片；以及包括 E-vita Open Plus 和 E-vita Open Neo 在内的主动脉弓支架。</p>
<h2>推荐阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Artivion</li>
<li>投资旅游股票的好处</li>
<li>特斯拉在刀尖上保持平衡：是时候谨慎行事了</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>为什么 Axon 的 16% 激增预示着公共安全技术的新纪元</li>
<li>电动车股票及其盈利方式</li>
<li>DraftKings 发布创纪录季度，瞄准盈利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFPUlQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFPUlQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Artivion 吗？</h2>
<p>在考虑 Artivion 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Artivion 并不在名单上。</p>
<p>虽然 Artivion 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AORT

<p>JMP Securities 将 Artivion (NYSE:AORT) 的目标股价从 33.00 美元上调至 42.00 美元，维持 “市场表现优于大盘” 的评级。这表明与前一交易日收盘价相比，潜在上涨幅度为 7.93%。其他分析师也提高了他们的目标价，Stifel Nicolaus 将其设定为 40.00 美元，Needham & Company 则为 45.00 美元。Artivion 的股票上涨了 19.0%，达到 38.92 美元，市场共识评级为 “买入”，平均目标价为 38.80 美元。该公司报告的季度每股收益为 0.24 美元，超出预期，营收同比增长 15.3%</p>

<p>Artivion (NYSE:AORT - Get Free Report) had its price objective upped by equities researchers at JMP Securities from $33.00 to $42.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a &#34;market outperform&#34; rating on the stock. JMP Securities' price objective suggests a potential upside of 7.93% from the company's previous close.</p>
<div class="lb-trans"><p>Artivion（纽约证券交易所代码：AORT - 获取免费报告）在周五向投资者发布的一份报告中，JMP Securities 的股票研究人员将其目标价格从 33.00 美元上调至 42.00 美元。该券商目前对该股票给予 “市场表现优于大盘” 的评级。JMP Securities 的目标价格暗示该公司股价有 7.93% 的潜在上涨空间。</p>
</div><p>A number of other equities research analysts have also recently weighed in on AORT. Stifel Nicolaus boosted their price objective on Artivion from $36.00 to $40.00 and gave the company a &#34;buy&#34; rating in a research note on Friday. Canaccord Genuity Group started coverage on Artivion in a report on Tuesday, June 17th. They issued a &#34;buy&#34; rating and a $35.00 target price on the stock. Citizens Jmp raised Artivion to a &#34;strong-buy&#34; rating in a report on Tuesday, May 6th. Finally, Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $45.00 target price (up previously from $32.00) on shares of Artivion in a report on Friday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and an average target price of $38.80.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也最近对 AORT 发表了看法。Stifel Nicolaus 在周五的研究报告中将 Artivion 的目标价格从 36.00 美元上调至 40.00 美元，并给予该公司 “买入” 评级。Canaccord Genuity Group 在 6 月 17 日的报告中开始覆盖 Artivion，给予 “买入” 评级和 35.00 美元的目标价格。Citizens Jmp 在 5 月 6 日的报告中将 Artivion 的评级提升至 “强力买入”。最后，Needham &amp; Company LLC 在周五的报告中重申了 “买入” 评级，并将目标价格上调至 45.00 美元（之前为 32.00 美元）。五位分析师对该股票给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，平均目标价格为 38.80 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Artivion</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Artivion 的最新分析</strong></p>
</div><h2>Artivion Trading Up 19.0%</h2>
<div class="lb-trans"><h2>Artivion 股价上涨 19.0%</h2>
</div><p>Shares of NYSE AORT traded up $6.22 during trading on Friday, hitting $38.92. 541,252 shares of the company were exchanged, compared to its average volume of 419,484. The company has a fifty day moving average price of $30.55 and a 200-day moving average price of $27.96. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.95 and a current ratio of 5.53. The firm has a market capitalization of $1.66 billion, a PE ratio of -77.80 and a beta of 1.64. Artivion has a 12-month low of $21.97 and a 12-month high of $40.56.</p>
<div class="lb-trans"><p>周五，NYSE AORT 的股票在交易中上涨 6.22 美元，达到 38.92 美元。该公司交易了 541,252 股，较其平均交易量 419,484 股有所增加。该公司的 50 日移动平均价格为 30.55 美元，200 日移动平均价格为 27.96 美元。该公司的债务与股本比率为 1.08，速动比率为 3.95，流动比率为 5.53。该公司的市值为 16.6 亿美元，市盈率为-77.80，贝塔值为 1.64。Artivion 的 12 个月低点为 21.97 美元，12 个月高点为 40.56 美元。</p>
</div><p>Artivion (NYSE:AORT - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.13. Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. The company had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. Artivion's quarterly revenue was up 15.3% on a year-over-year basis. As a group, equities research analysts expect that Artivion will post 0.37 EPS for the current year.</p>
<div class="lb-trans"><p>Artivion（纽约证券交易所代码：AORT - 获取免费报告）最近于 8 月 7 日发布了其财报。该公司报告本季度每股收益为 0.24 美元，超出市场共识预期的 0.11 美元，超出幅度为 0.13 美元。Artivion 的股本回报率为 3.63%，净利润率为-5.49%。该公司本季度的收入为 1.1297 亿美元，而市场共识预期为 1.0796 亿美元。Artivion 的季度收入同比增长 15.3%。作为一个整体，股票研究分析师预计 Artivion 在当前年度将发布 0.37 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, Director Anthony B. Semedo sold 2,600 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $28.47, for a total value of $74,022.00. Following the completion of the sale, the director owned 33,059 shares in the company, valued at approximately $941,189.73. This trade represents a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, SVP Jean F. Holloway sold 8,748 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $29.00, for a total value of $253,692.00. Following the completion of the sale, the senior vice president owned 178,510 shares of the company's stock, valued at approximately $5,176,790. This trade represents a 4.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,406 shares of company stock worth $1,801,262 over the last three months. 7.60% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Anthony B. Semedo 于 5 月 23 日星期五出售了 2,600 股该股票，交易价格为 28.47 美元，总价值为 74,022.00 美元。出售完成后，该董事在公司持有 33,059 股，价值约为 941,189.73 美元。此交易代表其持股比例减少了 7.29%。该交易已在证券交易委员会的备案中披露，您可以通过此链接访问。此外，SVP Jean F. Holloway 于 5 月 27 日星期二出售了 8,748 股该股票，交易价格为 29.00 美元，总价值为 253,692.00 美元。出售完成后，该高级副总裁持有 178,510 股公司股票，价值约为 5,176,790 美元。此交易代表其持股比例减少了 4.67%。该出售的披露信息可以在这里找到。过去三个月，内部人士共出售了 62,406 股公司股票，价值 1,801,262 美元。内部人士持有该股票的比例为 7.60%。</p>
</div><h2>Institutional Investors Weigh In On Artivion</h2>
<div class="lb-trans"><h2>机构投资者对 Artivion 的看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the business. Franklin Resources Inc. lifted its holdings in shares of Artivion by 2.8% in the 4th quarter. Franklin Resources Inc. now owns 21,707 shares of the company's stock worth $621,000 after purchasing an additional 600 shares during the last quarter. Illinois Municipal Retirement Fund lifted its holdings in shares of Artivion by 3.1% in the 1st quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock worth $504,000 after purchasing an additional 611 shares during the last quarter. MCF Advisors LLC lifted its holdings in shares of Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after purchasing an additional 614 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Artivion by 3.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company's stock worth $645,000 after purchasing an additional 727 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of Artivion by 1.2% in the 4th quarter. Barclays PLC now owns 71,697 shares of the company's stock worth $2,051,000 after purchasing an additional 820 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.</p>
<div class="lb-trans"><p>对该公司的股票，最近对冲基金进行了买入和卖出。Franklin Resources Inc.在第四季度将其在 Artivion 的持股增加了 2.8%。Franklin Resources Inc.目前持有 21,707 股该公司的股票，价值 621,000 美元，此前在上个季度购买了 600 股。伊利诺伊州市政退休基金在第一季度将其在 Artivion 的持股增加了 3.1%。伊利诺伊州市政退休基金目前持有 20,519 股该公司的股票，价值 504,000 美元，此前在上个季度购买了 611 股。MCF Advisors LLC 在第一季度将其在 Artivion 的持股增加了 109.3%。MCF Advisors LLC 目前持有 1,176 股该公司的股票，价值 29,000 美元，此前在上个季度购买了 614 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第四季度将其在 Artivion 的持股增加了 3.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 22,559 股该公司的股票，价值 645,000 美元，此前在上个季度购买了 727 股。最后，巴克莱银行在第四季度将其在 Artivion 的持股增加了 1.2%。巴克莱银行目前持有 71,697 股该公司的股票，价值 2,051,000 美元，此前在上个季度购买了 820 股。机构投资者和对冲基金持有该公司 86.37% 的股票。</p>
</div><h2>Artivion Company Profile</h2>
<div class="lb-trans"><h2>Artivion 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.</p>
<div class="lb-trans"><p>Artivion, Inc.在全球范围内制造、加工和分销医疗设备和可植入的人体组织。该公司提供 BioGlue，这是一种由牛血蛋白和交联蛋白的试剂组成的聚合物，适用于心脏、血管、神经和肺部手术；心脏保护服务；PhotoFix，一种牛心包补片；以及包括 E-vita Open Plus 和 E-vita Open Neo 在内的主动脉弓支架。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐阅读</h2>
</div><ul>
<li>Five stocks we like better than Artivion</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Tesla Is Balanced on a Knife Edge: Time to Tread Carefully</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li>
<li>EV Stocks and How to Profit from Them</li>
<li>DraftKings Posts Record Quarter, Eyes Profitability</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Artivion</li>
<li>投资旅游股票的好处</li>
<li>特斯拉在刀尖上保持平衡：是时候谨慎行事了</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>为什么 Axon 的 16% 激增预示着公共安全技术的新纪元</li>
<li>电动车股票及其盈利方式</li>
<li>DraftKings 发布创纪录季度，瞄准盈利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFPUlQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=AORT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Artivion Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Artivion 吗？</h2>
</div><p>Before you consider Artivion, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Artivion 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Artivion 并不在名单上。</p>
</div><p>While Artivion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Artivion 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Artivion（NYSE 代码：AORT）的目标股价被上调至 42.00 美元